DBV Technologies S.A. (DBVT)
DBV Technologies S.A. is a biopharmaceutical company focused on developing and commercializing innovative immunotherapy solutions for the treatment of food allergies. The company's flagship product, Viaskin, uses a patch-based delivery system aimed at desensitizing patients to specific allergens, particularly peanut allergies. Founded in France, DBV Technologies aims to address unmet medical needs through its proprietary epicutaneous immunotherapy platform.
Company News
DBV Technologies, a biopharmaceutical company, announced the filing of its 2024 Annual Report and Universal Registration Document, which include audited financial statements and other regulatory filings.
The Dow Jones index closed higher by around 50 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insi...
DBV Technologies S.A. (DBVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
"The New England Journal of Medicine" reported phase 3 trial details regarding the company's peanut allergy treatment for toddlers.
Check these three penny stocks out for your watchlist The post Penny Stocks to Buy With Gains in After Hours? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.